Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
Connock, M., Cummins, E. (Ewen), Sutcliffe, P. (Paul), Court, Rachel A., Johnson, Rhona, Grove, Amy L., Ngianga-Bakwin, Kandala, Mohiuddin, Syed and Clarke, Aileen, 1955- (2011) Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus. London: National Institute for Health and Clinical Excellence (NICE)..
WRAP_Clarke_NICE_Belimumab_56486.pdf - Published Version
Official URL: http://guidance.nice.org.uk/TA/Wave25/12/Consultat...
The manufacturer’s scope encompasses the clinical effectiveness and cost effectiveness of belimumab plus Standard of Care (SoC) relative to SoC alone, for the treatment of adults with active auto-antibody positive Systemic Lupus Erythematosus (SLE) and also for a subgroup of these patients who exhibit signs of high disease activity. According to the manufacturer’s scope and submission the population of greatest interest is the sub-group with high disease activity called the Target population. No subgroup is specified in the National Institute for Health and Clinical Excellence (NICE) scope. The Target population is a subgroup of the proposed licensed population; a decision on the manufacturer’s license application is awaited.
|Alternative Title:||Evidence review group report commissioned by the National Health Service Research & Development Programme on behalf of the National Institute for Health and Clinical Evidence|
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) > Warwick Evidence
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Systemic lupus erythematosus -- Treatment, Monoclonal antibodies|
|Publisher:||National Institute for Health and Clinical Excellence (NICE)|
|Place of Publication:||London|
|Official Date:||30 September 2011|
|Number of Pages:||166|
|Access rights to Published version:||Open Access|
|Funder:||NIHR Health Technology Assessment Programme (Great Britain)|
|Grant number:||10/73/01 (NIHR HTA)|
1. ACR Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis and Rheumatism 2004;50:3418-26.
Actions (login required)